Board Changes

Back to press releases

LONDON, UK, 15 September 2010 – Optos plc (LSE: OPTS), a leading medical retinal imaging company, today announces two board changes. On 1 October 2010, Dr Peter Kehoe will join the board as a non-executive director and at the same time Anne M. Glover will retire from the board as a non-executive director.

Anne Glover, CBE has been a non-executive director since 1996. Ms Glover is chief executive and co-founder of Amadeus Capital Partners, a European technology investor.

Dr. Peter (Pete) Kehoe, O.D., F.A.A.O is a practising optometrist. He is a past member of the Board of Trustees of the American Optometric Association (AOA) and served as president of the AOA in 2008-2009. He also consults broadly to the optometric and ophthalmic industries through Eye Care Solutions of which he is President.

Dr Peter Fellner, Chairman of Optos, commented: “We are hugely indebted to Anne for her years of service to Optos - as an early investor and in the skills she brought to the board during the company’s growth both pre and post IPO. We wish her well in her many endeavours. I am delighted to welcome Pete to the Board. His knowledge, experience and contacts in our key US market will be invaluable as we seek to expand our business.”

There are no further details to be disclosed in relation to the Financial Services Authority UK Listing Rules and Forms TM01 and AP01 respectively confirming the resignation of Ms Glover and appointment of Dr Kehoe will be submitted to the Registrar of Companies on 1 October 2010.

Enquiries

About Optos Plc

Optos plc is a leading retinal imaging company. Our vision is to be recognised as the leading provider of retinal diagnostics through leveraging our unique wide-field imaging technology. Both eye and non-eye diseases often first exhibit in the periphery of the retina. These are very difficult to detect clinically with conventional examination equipment and techniques. Optos' devices produce ultra wide-field, high resolution images of approximately 82% of the retina, something no other device is capable of doing in any one image. The images provide optometrists and ophthalmologists with enhanced clinical information which facilitates the early detection, management and treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers. Optos has a range of medical devices that support different customer segments and patient levels: the P200 device is concentrated on wellness screening carried out by optometrists and ophthalmologists in primary care; the P200C device is designed to meet the need for more exacting clinical imaging capabilities and standards in secondary care within the ophthalmology market and at optometric practices that are clinically managing a patient base with advanced ocular disease; and the P200MA device supports retinal specialists, working primarily with a diabetic patient base, in the medical care market through an advanced medical angiography procedure. Optos' technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for the practitioner and patient resulting in more targeted treatment regimes and improved patient outcomes. 75% of all blindness can be treated or prevented if diagnosed early enough and our Optos technology supports this objective.

For more information please visit our website www.optos.com

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates and projections about its industry, its beliefs and assumptions.  Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.